Amgen Inc BDR (AMGN34)

45.15
-0.17(-0.38%)
  • Volume:
    319
  • Bid/Ask:
    45.00/45.15
  • Day's Range:
    44.85 - 45.15

AMGN34 Overview

Prev. Close
45.32
Day's Range
44.85-45.15
Revenue
26.38B
Open
44.91
52 wk Range
39.23-48.52
EPS
11.89
Volume
319
Market Cap
676.16B
Dividend (Yield)
0.9907
(2.19%)
Average Volume (3m)
2,622
P/E Ratio
20.83
Beta
0.56
1-Year Change
5.13%
Shares Outstanding
534,930,850
Next Earnings Date
-
What is your sentiment on Amgen Inc BDR?
or
Market is currently closed. Voting is open during market hours.

Amgen Inc BDR News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Amgen Earnings, Revenue beat in Q2
    • ByInvesting.com-

    Investing.com - Amgen (NASDAQ:AMGN) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Amgen announced earnings per...

  • Amgen Tops Q1 EPS by 15c, Offers Guidance
    • ByInvesting.com-

    Amgen (NASDAQ:AMGN) reported Q1 EPS of $4.25, $0.15 better than the analyst estimate of $4.10. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of...

  • Amgen Earnings, Revenue beat in Q1
    • ByInvesting.com-

    Investing.com - Amgen (NASDAQ:AMGN) reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. Amgen announced earnings per...

Amgen Inc BDR Company Profile

Amgen Inc BDR Company Profile

Employees
24300
Market
Brazil
  • Type:Equity
  • Market:Brazil
  • ISIN:BRAMGNBDR004

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellSellStrong Buy
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Buy
SummaryBuyNeutralStrong SellStrong SellStrong Buy